Oncology Central

Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy


Despite the first reports of circulating cells from solid tumors shed light on the circulation in deceased and in living patients in 1869 [1] and the mid 1950s [2], respectively, it took almost 50 years until the introduction of the CellSearch® system by Veridex (now Janssen Diagnostics, LLC, Raritan, NJ, USA) as well as its approval by the US FDA [3] in 2004 paved the way for widespread clinical assessment of the number of circulating tumor cells (CTCs) as a prognostic diagnostic tool.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Visit our Spotlight homepage now to discover more content hosted on Oncology Central as part of our Spotlight on circulating tumor cells.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.